Foundational LCD, to be effective May 14, 2023, incorporates key feedback to 2022 draft, including updated guidelines recommending non-endoscopic biomarker testing Lucid positioned to submit EsoGuard for Technical Assessment and coverage under foundational LCD when sufficient clinical...
Read More Details
Finally We wish PressBee provided you with enough information of ( Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer )
Also on site :